This site is intended for healthcare professionals

Results from phase II CodeBreaK 100 show Lumakras is the first and only KRAS G12C inhibitor with overall survival data for NSCLC.-Amgen.

Read time: 1 mins
Last updated:28th Jun 2021
Published:6th Jun 2021
Amgen has presented data on overall survival, a secondary endpoint, from the Phase II results of the CodeBreaK 100 clinical study for Lumakras (sotorasib) in previously treated patients with non-small cell lung cancer (NSCLC) during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Condition: NSCLC/KRAS G12C
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest